Skip to content
Business Times – Lifestyle
Author:
Nasus Pharma, Ltd.
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
March 16, 2026
←
Previous Page
1
2